Utama › Limfoma Sel Mantel › California

Kajian klinikal Limfoma Sel Mantel di California

29 kajian untuk Limfoma Sel Mantel sedang mencari peserta di lokasi di California.

Bandar di California

Teks kajian rasmi (Bahasa Inggeris)

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Tower Cancer Research Foundation, Beverly Hills
Cedars-Sinai Medical Center, Los Angeles

Mengambil pesertaFasa 3

Umur 60 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05976763

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

University of California, Davis, Davis
University of California, Los Angeles, Los Angeles
University of California, San Diego, San Diego
dan 1 lagi

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06252675

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, La Jolla

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06542250

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Ucsf Fresno, Fresno
Kaiser Permanente Southern California, Irvine

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06742996

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Stanford Medicine, Palo Alto
UCLA Santa Monica Cancer Care, Santa Monica

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Stanford Cancer Center, Stanford

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06553872

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

City of Hope Comprehensive Cancer Center, Duarte

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07003295

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07691606

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT06340737

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Cedars-Sinai Medical Center, Los Angeles

Mengambil pesertaFasa 1

Umur 18 hingga 85 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT05887167

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Mengambil pesertaFasa 1/2

Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06675123

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT07424833

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

City of Hope, Duarte

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT07121946

DALY II USA/ MB-CART2019.1 for DLBCL

UC San Diego Health, La Jolla
Stanford University, Stanford

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT04545762

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical center, Duarte

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT03523975

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 20 Apr 2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
dan 1 lagi

Mengambil pesertaFasa 1/2

Umur 12 hingga 95 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 20 Mac 2026 · NCT04830137

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT06572618

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Feb 2026 · NCT05432635

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 5 Jan 2026 · NCT06054776

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 10 Dis 2025 · NCT05602363

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

City of Hope Medical Center, Duarte
Stanford University, Stanford

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 20 Nov 2025 · NCT05370430

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
dan 3 lagi

Mengambil pesertaKajian pemerhatian

Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Stanford Cancer Center, Palo Alto

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Ogo 2024 · NCT05255354

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.